Oxford BioMedica PLC Acquires Windrush Court Office And Laboratory Facilities
Oxford, UK – 13 October 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene and cell therapy company, announces that it has acquired the freehold of the Windrush Court office and laboratory facilities in Transport Way, Oxford, England, for a total cash consideration of £3.2 million from Oxford Real Estate Owner No. 2 Limited.
Windrush Court, a 6,684 sq m facility, is located directly opposite Oxford BioMedica’s manufacturing facility and the Company intends to relocate its laboratories and office activities there in stages before the current lease of the Medawar Centre, Oxford expires in March 2016. The purchase of Windrush Court will enable the Company to consolidate its entire activities in Transport Way, improving operational effectiveness, and will also provide additional capacity to accommodate the planned growth in business activities. As a result of the expected savings in rental costs and service charges, Oxford BioMedica expects to recover the purchase cost within 4 years.
-Ends-
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000
Media Enquiries:
Mary-Jane Elliott/Emma Thompson/Matthew Neal/Laura Thornton
Consilium Strategic Communications
Tel: +44 (0)20 7309 5700
Notes for editors
About Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy company with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world’s largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Company's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Company has licenced products and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.
Help employers find you! Check out all the jobs and post your resume.
Windrush Court, a 6,684 sq m facility, is located directly opposite Oxford BioMedica’s manufacturing facility and the Company intends to relocate its laboratories and office activities there in stages before the current lease of the Medawar Centre, Oxford expires in March 2016. The purchase of Windrush Court will enable the Company to consolidate its entire activities in Transport Way, improving operational effectiveness, and will also provide additional capacity to accommodate the planned growth in business activities. As a result of the expected savings in rental costs and service charges, Oxford BioMedica expects to recover the purchase cost within 4 years.
-Ends-
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000
Media Enquiries:
Mary-Jane Elliott/Emma Thompson/Matthew Neal/Laura Thornton
Consilium Strategic Communications
Tel: +44 (0)20 7309 5700
Notes for editors
About Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy company with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world’s largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Company's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Company has licenced products and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.
Help employers find you! Check out all the jobs and post your resume.